Plain-English translation of NCT07761936 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether a medication called can help reduce pain in people with Parkinson's disease who have motor fluctuations (times when their symptoms get better or worse throughout the day). Half of the 60 participants will receive the medication, and half will receive a look-alike placebo pill. Both groups will be followed for 12 weeks to see if the medication works better than placebo at relieving pain.
Many people with Parkinson's disease experience chronic pain alongside their movement symptoms, and this pain often doesn't improve with standard Parkinson's treatments alone. This study is exploring whether this medication might help fill that gap and offer relief to patients who are still suffering despite being on stable doses of their regular Parkinson's drugs.
You likely qualify if…
You likely don't qualify if…
You will visit the study center at the University of Verona and be randomly assigned to receive either the new medication or a placebo pill, taken once daily by mouth. You'll start with a lower dose for the first week, then increase to the full dose for the remaining 11 weeks. During those 12 weeks, you'll complete pain rating scales, motor symptom assessments, and quality-of-life questionnaires to help researchers understand how well the treatment is working.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
Italy